1
Home
Companies

Allakos

#9765

Rank

$29.69M

Marketcap

US United States

Country

Allakos
Leadership team

Dr. Robert Alexander Ph.D. (CEO & Director)

Dr. Adam L. Tomasi Ph.D. (Pres & COO)

Mr. Baird Radford III (Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
San Carlos, California, United States
Established
2012
Company Registration
SEC CIK number: 0001564824
Traded as
ALLK
Social Media
URL
https://www.allakos.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
History

Allakos was founded as a private company in 2012 in Redwood City, California, to develop antibodies to AK155, a target believed to be a major contributor to the allergic, proliferative and/or immunologic reactions involved in certain diseases. Allakos went public in July 2018.

Mission
Our mission is to create new treatments that improve the lives of patients with certain allergic, immunologic, and proliferative diseases.
Vision
Our vision is to discover and develop breakthrough therapies that are safe, effective, and accessible to all.
Key Team

Dr. Henrik Sandvad Rasmussen (Strategic Advisor)

Dr. Craig Paterson M.D. (Chief Medical Officer)

Brad Youngblood (Head of Research)

Mr. Alan Chang (Director of Medical Affairs & Data Analytics)

Recognition and Awards
Allakos has won numerous awards, including the FierceBiotech Breakthrough Award for Drug Discovery in 2021, the Red Herring Top 100 Most Innovative Company in 2020, and the Scrip Award for Best Immunology Deal in 2019.
References

https://in.investing.com/equities/allakos-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/allakos

https://finance.yahoo.com/quote/allk/

https://www.allakos.com

https://sec.report/CIK/0001564824

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Allakos
Leadership team

Dr. Robert Alexander Ph.D. (CEO & Director)

Dr. Adam L. Tomasi Ph.D. (Pres & COO)

Mr. Baird Radford III (Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Headquarters
San Carlos, California, United States
Established
2012
Company Registration
SEC CIK number: 0001564824
Traded as
ALLK
Social Media
URL
https://www.allakos.com